Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1210/jendso/bvaa102 http://scihub22266oqcxt.onion/10.1210/jendso/bvaa102 32885126!7454711!32885126     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32885126&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Endocr+Soc 2020 ; 4 (9): bvaa102 Nephropedia Template TP {{tp|p=32885126|t=2020. Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients |pdf=|usr=}}{{32885126}} gab.com Text Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients JO: J Endocr Soc http://www.kidney.de/pget.php?&tw=1&pmid=32885126 #FOAvip Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately affect those with hypertension and diabetes. Because of inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10-15; n = 12 870; I (2): 89%), and 17% (95% CI, 13-22; n = 12 709; I (2): 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I (2): 0%) and 32% (95% CI, 16-54; n = 1078; I (2): 63%), respectively. Unadjusted relative risk for intensive care unit admission and mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I (2): 80%; P = .008) and 2.78 (95% CI, 1.39-5.58; n = 2058; I (2): 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; I (2): 0%; P < .001) and 2.39 (95% CI, 1.54-3.73; n = 3107; I (2): 66%; P < .001) for hypertensives. Neither diabetes (1.50; 95% CI, 0.90-2.50; n = 1991; I (2): 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; n = 2023; I (2): 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared with those without these comorbidities. PROSPERO REGISTRATION NUMBER: CRD42020176582. Twit Text FOAVip Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients ????J Endocr Soc http://www.kidney.de/pget.php?&tw=1&pmid=32885126 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32885126 #FOAvip English Wikipedia <ref>{{Cite pmid|32885126}}</ref> Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients #MMPMID32885126 Barrera FJ; Shekhar S; Wurth R; Moreno-Pena PJ; Ponce OJ; Hajdenberg M; Alvarez-Villalobos NA; Hall JE; Schiffrin EL; Eisenhofer G; Porter F; Brito JP; Bornstein SR; Stratakis CA; Gonzalez-Gonzalez JG; Rodiguez-Gutierrez R; Hannah-Shmouni F J Endocr Soc 2020[Sep]; 4 (9): bvaa102 PMID32885126show ga Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately affect those with hypertension and diabetes. Because of inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10-15; n = 12 870; I (2): 89%), and 17% (95% CI, 13-22; n = 12 709; I (2): 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I (2): 0%) and 32% (95% CI, 16-54; n = 1078; I (2): 63%), respectively. Unadjusted relative risk for intensive care unit admission and mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I (2): 80%; P = .008) and 2.78 (95% CI, 1.39-5.58; n = 2058; I (2): 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; I (2): 0%; P < .001) and 2.39 (95% CI, 1.54-3.73; n = 3107; I (2): 66%; P < .001) for hypertensives. Neither diabetes (1.50; 95% CI, 0.90-2.50; n = 1991; I (2): 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; n = 2023; I (2): 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared with those without these comorbidities. PROSPERO REGISTRATION NUMBER: CRD42020176582. ?Prevalence of Diabetes and Hypertension and Their Associated Risks for(epmc).pdf DeepDyve Pubget Overpricing